| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute-On-Chronic Liver Failure | 15 | 2024 | 62 | 6.380 |
Why?
|
| Carcinoma, Hepatocellular | 19 | 2024 | 2165 | 3.630 |
Why?
|
| End Stage Liver Disease | 9 | 2023 | 186 | 3.370 |
Why?
|
| Liver Cirrhosis | 28 | 2024 | 1026 | 3.060 |
Why?
|
| Liver Neoplasms | 20 | 2024 | 4795 | 2.730 |
Why?
|
| Liver Transplantation | 15 | 2024 | 1184 | 2.400 |
Why?
|
| Fatty Liver | 10 | 2013 | 257 | 2.180 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 17 | 2023 | 440 | 2.100 |
Why?
|
| Liver Diseases | 3 | 2024 | 605 | 1.660 |
Why?
|
| Hepatitis C | 3 | 2023 | 549 | 1.490 |
Why?
|
| Hepatitis C, Chronic | 3 | 2021 | 468 | 1.160 |
Why?
|
| Postal Service | 1 | 2024 | 17 | 0.980 |
Why?
|
| Patient Navigation | 1 | 2024 | 32 | 0.950 |
Why?
|
| Isoflavones | 1 | 2022 | 76 | 0.810 |
Why?
|
| Duodenal Diseases | 2 | 2019 | 47 | 0.790 |
Why?
|
| Graft Survival | 3 | 2024 | 1093 | 0.790 |
Why?
|
| Gastroparesis | 1 | 2022 | 81 | 0.770 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 1331 | 0.750 |
Why?
|
| Humans | 93 | 2024 | 271062 | 0.700 |
Why?
|
| Frailty | 1 | 2022 | 129 | 0.700 |
Why?
|
| Severity of Illness Index | 14 | 2023 | 4389 | 0.690 |
Why?
|
| Exercise Therapy | 1 | 2022 | 292 | 0.670 |
Why?
|
| Telemedicine | 2 | 2023 | 548 | 0.650 |
Why?
|
| Syphilis | 1 | 2019 | 99 | 0.640 |
Why?
|
| Penicillins | 1 | 2019 | 166 | 0.640 |
Why?
|
| Organ Transplantation | 1 | 2021 | 204 | 0.640 |
Why?
|
| Lipase | 4 | 2020 | 122 | 0.630 |
Why?
|
| Publication Bias | 1 | 2018 | 37 | 0.630 |
Why?
|
| Alcohol Drinking | 3 | 2021 | 591 | 0.630 |
Why?
|
| Endoscopy, Digestive System | 1 | 2019 | 210 | 0.610 |
Why?
|
| Probiotics | 2 | 2018 | 240 | 0.610 |
Why?
|
| Prevalence | 12 | 2021 | 3417 | 0.600 |
Why?
|
| Testosterone | 1 | 2021 | 733 | 0.510 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2018 | 211 | 0.510 |
Why?
|
| Quality of Life | 5 | 2022 | 4740 | 0.500 |
Why?
|
| Sodium | 3 | 2020 | 353 | 0.490 |
Why?
|
| Anxiety | 2 | 2023 | 1233 | 0.460 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2015 | 75 | 0.460 |
Why?
|
| Risk Assessment | 5 | 2023 | 6832 | 0.450 |
Why?
|
| Prognosis | 11 | 2024 | 22464 | 0.440 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1445 | 0.440 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 878 | 0.440 |
Why?
|
| Ascites | 3 | 2024 | 216 | 0.440 |
Why?
|
| Protein Phosphatase 1 | 1 | 2013 | 79 | 0.420 |
Why?
|
| Membrane Proteins | 5 | 2020 | 2959 | 0.420 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 148 | 0.400 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 120 | 0.400 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2022 | 247 | 0.390 |
Why?
|
| Palliative Care | 2 | 2020 | 2155 | 0.390 |
Why?
|
| Vitamin D | 1 | 2013 | 261 | 0.370 |
Why?
|
| Deglutition Disorders | 1 | 2015 | 487 | 0.360 |
Why?
|
| Depression | 1 | 2020 | 1737 | 0.360 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 4507 | 0.340 |
Why?
|
| Organ Dysfunction Scores | 2 | 2020 | 70 | 0.340 |
Why?
|
| Antiviral Agents | 4 | 2021 | 1254 | 0.340 |
Why?
|
| Helicobacter pylori | 3 | 2024 | 1434 | 0.330 |
Why?
|
| United States | 14 | 2023 | 16011 | 0.330 |
Why?
|
| Helicobacter Infections | 3 | 2024 | 1351 | 0.330 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2021 | 25 | 0.330 |
Why?
|
| Diet | 3 | 2022 | 1487 | 0.310 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2024 | 967 | 0.310 |
Why?
|
| Hepacivirus | 2 | 2021 | 421 | 0.310 |
Why?
|
| Gastroesophageal Reflux | 2 | 2024 | 365 | 0.300 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2013 | 1468 | 0.300 |
Why?
|
| Myotomy | 2 | 2017 | 17 | 0.290 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 1522 | 0.290 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6187 | 0.290 |
Why?
|
| Colon | 3 | 2021 | 689 | 0.290 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2019 | 192 | 0.290 |
Why?
|
| Alcohol Abstinence | 2 | 2017 | 17 | 0.290 |
Why?
|
| Secondary Prevention | 2 | 2020 | 321 | 0.280 |
Why?
|
| Nutrition Surveys | 5 | 2020 | 316 | 0.280 |
Why?
|
| Ultrasonography | 5 | 2021 | 1938 | 0.280 |
Why?
|
| Inflammation | 1 | 2017 | 2525 | 0.280 |
Why?
|
| Cohort Studies | 8 | 2022 | 9438 | 0.270 |
Why?
|
| Liver | 6 | 2021 | 3124 | 0.270 |
Why?
|
| Retrospective Studies | 22 | 2024 | 39721 | 0.270 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 352 | 0.260 |
Why?
|
| Intestinal Mucosa | 3 | 2021 | 1124 | 0.250 |
Why?
|
| Biopsy | 4 | 2023 | 3544 | 0.240 |
Why?
|
| Treatment Outcome | 11 | 2024 | 33851 | 0.240 |
Why?
|
| Paracentesis | 1 | 2024 | 22 | 0.240 |
Why?
|
| Bacteria | 2 | 2019 | 652 | 0.240 |
Why?
|
| Weight Loss | 3 | 2023 | 639 | 0.240 |
Why?
|
| Hernia, Hiatal | 1 | 2024 | 67 | 0.230 |
Why?
|
| Male | 29 | 2024 | 128516 | 0.230 |
Why?
|
| Fundoplication | 1 | 2024 | 70 | 0.230 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 63 | 0.230 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2023 | 94 | 0.230 |
Why?
|
| Hepatic Encephalopathy | 2 | 2023 | 89 | 0.230 |
Why?
|
| Gastroenterologists | 1 | 2023 | 21 | 0.220 |
Why?
|
| Hypertension, Portal | 2 | 2024 | 129 | 0.220 |
Why?
|
| Middle Aged | 25 | 2024 | 90103 | 0.220 |
Why?
|
| Early Diagnosis | 1 | 2024 | 315 | 0.210 |
Why?
|
| Tissue Donors | 3 | 2022 | 812 | 0.210 |
Why?
|
| Anti-Obesity Agents | 1 | 2022 | 32 | 0.210 |
Why?
|
| Herniorrhaphy | 1 | 2024 | 179 | 0.210 |
Why?
|
| Allografts | 2 | 2021 | 684 | 0.210 |
Why?
|
| Plasma Exchange | 1 | 2023 | 103 | 0.210 |
Why?
|
| Morbidity | 1 | 2023 | 404 | 0.200 |
Why?
|
| Hemochromatosis | 1 | 2022 | 39 | 0.200 |
Why?
|
| Risk Factors | 12 | 2022 | 17829 | 0.200 |
Why?
|
| Bacterial Infections | 2 | 2016 | 507 | 0.200 |
Why?
|
| Aged | 19 | 2024 | 73250 | 0.200 |
Why?
|
| Genetic Pleiotropy | 1 | 2021 | 28 | 0.200 |
Why?
|
| Physical Fitness | 1 | 2022 | 125 | 0.200 |
Why?
|
| Biliary Atresia | 1 | 2024 | 201 | 0.190 |
Why?
|
| Global Burden of Disease | 1 | 2021 | 29 | 0.190 |
Why?
|
| Bacterial Translocation | 2 | 2024 | 28 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 3174 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 2673 | 0.180 |
Why?
|
| Genome-Wide Association Study | 3 | 2021 | 2084 | 0.180 |
Why?
|
| Adult | 22 | 2023 | 81619 | 0.180 |
Why?
|
| Hospital Mortality | 2 | 2024 | 1313 | 0.180 |
Why?
|
| Esophageal Achalasia | 2 | 2017 | 41 | 0.170 |
Why?
|
| Treponema pallidum | 1 | 2019 | 50 | 0.170 |
Why?
|
| Female | 26 | 2024 | 148623 | 0.170 |
Why?
|
| Hyperkalemia | 1 | 2021 | 80 | 0.170 |
Why?
|
| Abdominal Cavity | 1 | 2019 | 23 | 0.170 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 235 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 623 | 0.170 |
Why?
|
| Serologic Tests | 1 | 2019 | 149 | 0.160 |
Why?
|
| Acute Kidney Injury | 3 | 2024 | 780 | 0.160 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2023 | 676 | 0.160 |
Why?
|
| Patient Care Planning | 1 | 2020 | 306 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 5187 | 0.160 |
Why?
|
| Disease Progression | 4 | 2024 | 6898 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2023 | 699 | 0.150 |
Why?
|
| Mortality | 1 | 2020 | 353 | 0.150 |
Why?
|
| Biomarkers | 3 | 2024 | 5107 | 0.150 |
Why?
|
| Hemochromatosis Protein | 2 | 2022 | 24 | 0.150 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2017 | 11 | 0.150 |
Why?
|
| Esophagitis, Peptic | 1 | 2017 | 39 | 0.140 |
Why?
|
| Transition to Adult Care | 1 | 2019 | 113 | 0.140 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2016 | 10 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2021 | 567 | 0.140 |
Why?
|
| Alcohol-Related Disorders | 1 | 2017 | 43 | 0.140 |
Why?
|
| Ileus | 1 | 2016 | 29 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 1066 | 0.140 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2016 | 17 | 0.140 |
Why?
|
| Ablation Techniques | 1 | 2018 | 150 | 0.140 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2017 | 68 | 0.140 |
Why?
|
| Immunotherapy | 2 | 2022 | 3535 | 0.140 |
Why?
|
| Stomach Diseases | 1 | 2016 | 73 | 0.130 |
Why?
|
| Esophageal Diseases | 1 | 2016 | 79 | 0.130 |
Why?
|
| Prebiotics | 1 | 2015 | 35 | 0.120 |
Why?
|
| Appendectomy | 1 | 2016 | 127 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 807 | 0.120 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 201 | 0.120 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2015 | 89 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2019 | 707 | 0.120 |
Why?
|
| Suture Techniques | 1 | 2016 | 292 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 725 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2017 | 419 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 863 | 0.120 |
Why?
|
| Colectomy | 1 | 2016 | 290 | 0.120 |
Why?
|
| Mexican Americans | 2 | 2013 | 328 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2023 | 6034 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 450 | 0.110 |
Why?
|
| Hospitalization | 2 | 2024 | 2198 | 0.110 |
Why?
|
| Endoscopy | 1 | 2017 | 496 | 0.110 |
Why?
|
| Time Factors | 5 | 2021 | 13112 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 849 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2017 | 648 | 0.110 |
Why?
|
| Gene Frequency | 2 | 2013 | 1187 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2016 | 254 | 0.110 |
Why?
|
| Genotype | 3 | 2022 | 4111 | 0.110 |
Why?
|
| Menstruation | 1 | 2012 | 37 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2018 | 1522 | 0.110 |
Why?
|
| Contraceptives, Oral | 1 | 2012 | 57 | 0.110 |
Why?
|
| Patient Selection | 1 | 2020 | 2041 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2018 | 829 | 0.100 |
Why?
|
| Mutation | 2 | 2022 | 15861 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 5438 | 0.100 |
Why?
|
| Hyperuricemia | 1 | 2013 | 49 | 0.100 |
Why?
|
| Gastroenterology | 1 | 2015 | 199 | 0.100 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 345 | 0.100 |
Why?
|
| Uric Acid | 1 | 2013 | 121 | 0.100 |
Why?
|
| Pancreatitis | 1 | 2015 | 292 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 5908 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 4982 | 0.100 |
Why?
|
| alpha-Fetoproteins | 2 | 2023 | 256 | 0.100 |
Why?
|
| Sepsis | 1 | 2017 | 688 | 0.090 |
Why?
|
| Veterans | 2 | 2021 | 1773 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 2316 | 0.090 |
Why?
|
| Obesity | 2 | 2022 | 2940 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2016 | 772 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4887 | 0.090 |
Why?
|
| Cognition | 1 | 2016 | 981 | 0.090 |
Why?
|
| Mass Screening | 1 | 2018 | 1553 | 0.080 |
Why?
|
| Length of Stay | 3 | 2024 | 2009 | 0.080 |
Why?
|
| Waiting Lists | 2 | 2021 | 265 | 0.080 |
Why?
|
| Asia | 2 | 2021 | 153 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2015 | 1547 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 10351 | 0.080 |
Why?
|
| Young Adult | 7 | 2019 | 22063 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2018 | 1368 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2019 | 3067 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 1066 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2021 | 508 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2023 | 13375 | 0.080 |
Why?
|
| Incidence | 1 | 2018 | 5842 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2015 | 802 | 0.070 |
Why?
|
| Europe | 2 | 2020 | 647 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 3662 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2013 | 2089 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2017 | 372 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 30966 | 0.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2015 | 1821 | 0.060 |
Why?
|
| Diethylpropion | 1 | 2022 | 2 | 0.050 |
Why?
|
| Phentermine | 1 | 2022 | 5 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2022 | 2852 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 53 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2023 | 155 | 0.050 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2024 | 98 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 16 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2024 | 152 | 0.050 |
Why?
|
| Neurocan | 2 | 2013 | 3 | 0.050 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 2 | 2013 | 42 | 0.050 |
Why?
|
| Naltrexone | 1 | 2022 | 99 | 0.050 |
Why?
|
| Bupropion | 1 | 2022 | 76 | 0.050 |
Why?
|
| Prothrombin | 1 | 2022 | 37 | 0.050 |
Why?
|
| Metaplasia | 1 | 2023 | 386 | 0.050 |
Why?
|
| Hydrogels | 1 | 2022 | 126 | 0.050 |
Why?
|
| Ferritins | 1 | 2022 | 155 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 32 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 26 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2021 | 53 | 0.050 |
Why?
|
| Donor Selection | 1 | 2022 | 106 | 0.050 |
Why?
|
| Lectins, C-Type | 2 | 2013 | 161 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2021 | 2286 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2021 | 79 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 15249 | 0.050 |
Why?
|
| Simvastatin | 1 | 2021 | 100 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 1400 | 0.040 |
Why?
|
| Sex Factors | 2 | 2017 | 2191 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2020 | 183 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2024 | 592 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2023 | 960 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Research Design | 2 | 2020 | 1573 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 1031 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2023 | 1076 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 486 | 0.040 |
Why?
|
| Attitude | 1 | 2019 | 163 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 604 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 347 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 505 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2022 | 519 | 0.040 |
Why?
|
| Aftercare | 1 | 2019 | 254 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 318 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 746 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 865 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 5237 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 604 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 104 | 0.040 |
Why?
|
| Comorbidity | 1 | 2023 | 2434 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 7936 | 0.030 |
Why?
|
| Communication | 1 | 2022 | 856 | 0.030 |
Why?
|
| Risk | 1 | 2020 | 1913 | 0.030 |
Why?
|
| Sutures | 1 | 2016 | 93 | 0.030 |
Why?
|
| Intraabdominal Infections | 1 | 2015 | 4 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 1113 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2015 | 33 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1213 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 14682 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 647 | 0.030 |
Why?
|
| Adolescent | 3 | 2024 | 32554 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 4328 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2016 | 239 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 421 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1111 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 1573 | 0.030 |
Why?
|
| Lysophospholipase | 1 | 2013 | 4 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1263 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1597 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 148 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 240 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2013 | 223 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2011 | 169 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2011 | 186 | 0.020 |
Why?
|
| Kidney | 1 | 2019 | 2266 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 341 | 0.020 |
Why?
|
| Survival Rate | 1 | 2024 | 12518 | 0.020 |
Why?
|
| Child | 2 | 2024 | 30373 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6464 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 754 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3861 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2011 | 337 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1254 | 0.020 |
Why?
|
| Infant | 1 | 2024 | 13876 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 4884 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 7786 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 2287 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 2427 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6251 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 13979 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1288 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 3431 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 1182 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 9305 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 1510 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 4332 | 0.010 |
Why?
|
| Age Factors | 1 | 2013 | 5487 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 5087 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 10701 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2017 | 5683 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 3907 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 7927 | 0.010 |
Why?
|